With the rapid progress in molecular biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams and research programs leveraging molecular oncology and new technologies. To address the national shortage of surgical investigators focused on surgical oncology, the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center has dedicated its T32 training program to producing academic surgical oncologists. The long-term objective is to train surgical residents and surgical oncology fellows in the essential research skills necessary to be productive independent surgical investigators, and leaders in surgical oncology. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic surgical oncology, including minority individuals and women. Training is offered to postdoctoral M.D. or M.D. Ph.D. fellows either during a 24-month hiatus from general surgery residency training or during a three-year clinical/research fellowship in surgical oncology that begins after general surgery residency. Our T32 training program has been highly successful in achieving its goals and is now entering its 25th year. Upon completion of their residency training, most of our T32 research fellows either started fellowship training, or accepted academic surgical positions. Upon completion of their surgical oncology fellowship training, all of our T32 clinical/research fellows entered academic Surgical Oncology positions. Our T32 program provides research opportunities in a broad range of basic oncologic disciplines, including cancer biology, molecular oncology, cell signaling, nanotechnology, molecular therapeutics, biomarker development and validation, clinical trials, clinical effectiveness and outcomes research. This academic training program allows us to train surgeons with a diverse set of unique skills, increasing the likelihood of trainees obtaining an academic position upon completion of training. Training in biostatistics, and the responsible conduct of research, and a rich array of seminars and graduate courses are integral to this T32 program. The T32 program faculty includes established surgical investigators and full-time academic basic science researchers, all of whom have peer-reviewed grant support. Programs at the Texas Medical Center provide our trainees access to resources and potential collaborators at six academic institutions. Thus, the University of Texas MD Anderson Cancer Center is a highly stimulating environment for aspiring academic surgical oncologists.
With the rapid progress in molecular biology, there is a great need to train academic surgical oncologists that can not only deliver state of the art surgical care, but can also lead multidisciplinary teams as well as research programs leveraging molecular oncology and new technologies. The goal of this T32 training program is to train surgical trainees in the essential research skills necessary to be productive independent surgical investigators and leaders in surgical oncology.
|Kim, B J; Day, R W; Davis, C H et al. (2017) Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective. J Thromb Haemost 15:2158-2164|
|Roife, David; Kang, Ya'an; Wang, Li et al. (2017) Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery 161:1246-1254|
|Gall, Victor A; Philips, Anne V; Qiao, Na et al. (2017) Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res 77:5374-5383|
|Arango, Natalia Paez; Brusco, Lauren; Mills Shaw, Kenna R et al. (2017) A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8:41806-41814|
|Voss, Rachel K; Chiang, Yi-Ju; Torres, Keila E et al. (2017) Adherence to National Comprehensive Cancer Network Guidelines is Associated with Improved Survival for Patients with Stage 2A and Stages 2B and 3 Extremity and Superficial Trunk Soft Tissue Sarcoma. Ann Surg Oncol 24:3271-3278|
|Dai, Bingbing; Roife, David; Kang, Ya'an et al. (2017) Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther 16:662-670|
|Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:|
|Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2017) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg :|
|Voss, Rachel K; Feng, Lei; Lee, Jeffrey E et al. (2017) Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab 102:2807-2813|
|Evans, Kurt W; Yuca, Erkan; Akcakanat, Argun et al. (2017) A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res 23:6468-6477|
Showing the most recent 10 out of 177 publications